The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival
Open accessAbstract
Purpose: Older men are more likely to be diagnosed with high-risk prostate cancer and to have lower overall survival. As a result, age often plays a role in treatment choice. However, the relationships among age, disease risk, and prostate cancer–specific survival have not been well established. Patients and Methods: We studied men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database with complete risk, treatment, and follow-up information. High-risk patients were identified by using the validated Cancer of the Prostate Risk Assessment (CAPRA) score. Competing risks regression was used to identify the independent impact of age on cancer-specific survival. We also analyzed the effect of local treatment on survival among older men with high-risk disease. Results: In all, 26% of men age ≥ 75 years presented with high-risk disease (CAPRA score 6 to 10). Treatment varied markedly with age across risk strata; older men were more likely to receive androgen deprivation monotherapy. Controlling for treatment modality alone, or for treatment and risk, age did not independently predict cancer-specific survival. Furthermore, controlling for age, comorbidity, and risk, older men with high-risk tumors receiving local therapy had a 46% reduction in mortality compared with those treated conservatively. Conclusion: Older patients are more likely to have high-risk prostate cancer at diagnosis and less likely to receive local therapy. Indeed, underuse of potentially curative local therapy among older men with high-risk disease may in part explain observed differences in cancer-specific survival across age strata. These findings support making decisions regarding treatment on the basis of disease risk and life expectancy rather than on chronologic age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Deaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Eastham, J. A., Stapleton, A. M. F., Wheeler, T. M., & Scardino, P. T. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.10.766 · Cited by 1,242
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Self-citationEpidemiology of prostate cancer
Crawford, E. D. (2003) · Urology · doi:10.1016/j.urology.2003.10.013 · Cited by 543
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
Cooperberg, M. R., & Carroll, P. R. (2015) · JAMA · doi:10.1001/jama.2015.6036 · Cited by 609
Self-citationHigh-risk prostate cancer—classification and therapy
Chang, A. J., Autio, K. A., Roach, M., & Scher, H. I. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.68 · Cited by 500
Active Surveillance for Prostate Cancer: Progress and Promise
Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9738 · Cited by 290
Self-citationPreoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy
Clendinen, C. S., Gaul, D. A., Monge, M. E., Arnold, R. S., Edison, A. S., Petros, J. A., & Fernández, F. M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00926 · Cited by 39
Metadata
- Authors
- Bechis, S. K., Carroll, P. R., & Cooperberg, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-10
- Volume
- 29
- Issue
- 2
- Pages
- 235-241
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108081829
- Cited by
- 392
- References
- 37
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. https://app.cochat.ai/papers/10.1200/jco.2010.30.2075
- The paper
- Bechis, S. K., Carroll, P. R., & Cooperberg, M. R. (2011). Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.30.2075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.